TIMOLIDE (Timolol Maleate-Hydrochlorothiazide) is for the treatment of hypertension. It combines the antihypertensive activity of two agents: a non-selective beta-adrenergic receptor blocking agent (timolol maleate) and a diuretic (hydrochlorothiazide).
TIMOLIDE is indicated for the treatment of hypertension.
This fixed combination drug is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to an individual patient's needs, it may be more convenient than the separate components.
Media Articles Related to Timolide (Timolol / Hydrochlorothiazide)
Getting to the root of pulmonary hypertension by zooming in on arteries
Source: Hypertension News From Medical News Today [2014.03.03]
You might think building muscle is a good thing, but that's often not so in the case of blood vessels in adults. In fact, excess smooth muscle is a root problem in many vascular diseases, as it causes arteries to constrict and blood pressure to rise. Now, an in-depth analysis of arterioles in mice with pulmonary hypertension explains how those misplaced smooth muscle cells develop.
Breast cancer treatments could increase risk of developing osteoporosis or hypertension
Source: Bones / Orthopedics News From Medical News Today [2014.02.28]
Older women who have overcome breast cancer are likely to struggle with heart disease, osteoporosis and hypertension further on in their lives. Whether these conditions occur or not is influenced by the treatment that patients received to fight cancer, their overall weight and their age.
10 of 11 new gene signals are likely drug targets for hypertension
Source: Hypertension News From Medical News Today [2014.02.24]
A large international study analyzing genes in tens of thousands of individuals has discovered 11 new genetic signals associated with blood pressure levels. Ten of those signals are in or very near genes encoding proteins that appear to be likely targets for drugs already in existence or in development.
Opsumit approved by SwissMedic for pulmonary arterial hypertension
Source: Hypertension News From Medical News Today [2014.02.17]
Actelion Ltd has announced that SwissMedic has approved Opsumit® (macitentan) for PAH patients within Switzerland.Opsumit is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in patients of WHO Functional Class II to III to reduce morbidity and the risk of mortality.
Air pollution increases risk for hypertension in pregnant women
Source: Hypertension News From Medical News Today [2014.02.14]
Breathing the air outside their homes may be just as toxic to pregnant women - if not more so - as breathing in cigarette smoke, increasing a mom-to-be's risk of developing deadly complications such as preeclampsia, according to findings from a new University of Florida study.
Published Studies Related to Timolide (Timolol / Hydrochlorothiazide)
The efficacy of hydrochlorothiazide, timolol and enalapril in Ethiopians with essential hypertension. [1992.07]
A double-blind trial of hydrochlorothiazide, timolol and enalapril was carried out in Ethiopians with essential hypertension at the Tikur Anbessa Hospital, Addis Abeba, between 1987 and 1990. Patients with a supine diastolic blood pleasure of 95-120 mmHg after a washout period of 2 weeks were randomized to receive hydrochlorothiazide 25 mg daily, timolol 10 mg daily or enalapril 10 mg daily...
Combined action of enalapril or timolol with hydrochlorothiazide plus amiloride in hypertension. 
59 mild to moderate hypertensives were treated for four weeks with 50 mg hydrochlorothiazide plus 5 mg of amiloride, then concomitantly with these diuretics with either enalapril (10-20 mg) or timolol (10-20 mg) in two parallel treatment groups for an additional 12 weeks in an open study... Both drug combinations can be considered efficient, well tolerated and safe in the treatment of mild to moderate hypertension.